D
David R. Koehler
Researcher at University of Toronto
Publications - 18
Citations - 960
David R. Koehler is an academic researcher from University of Toronto. The author has contributed to research in topics: Genetic enhancement & Cystic fibrosis. The author has an hindex of 14, co-authored 18 publications receiving 922 citations. Previous affiliations of David R. Koehler include Canadian Institutes of Health Research.
Papers
More filters
Journal ArticleDOI
Gene transfer of CFTR to airway epithelia: low levels of expression are sufficient to correct Cl- transport and overexpression can generate basolateral CFTR.
Sara L. Farmen,Philip H. Karp,Philip Ng,Donna Palmer,David R. Koehler,Jim Hu,Arthur L. Beaudet,Joseph Zabner,Michael J. Welsh +8 more
TL;DR: It is suggested that very little CFTR is required in a fraction of CF epithelial cells to complement Cl(-) transport because transepithelial Cl(+) flow is limited at the basolateral membrane, and a broad leeway in promoter strength for correcting the CF gene transfer is suggested.
Journal ArticleDOI
Lung Inflammation as a Therapeutic Target in Cystic Fibrosis
TL;DR: The mechanisms responsible for inflammation in the CF lung are examined, potential therapeutic strategies targeting inflammation are discussed, and potential therapeutic strategy targeting inflammation is discussed.
Journal ArticleDOI
Adenoviral vectors for gene replacement therapy.
TL;DR: Current developments in vector design and delivery methods have improved the potential of Ads for successful gene therapy application, and major obstacles to their clinical application have been identified.
Journal ArticleDOI
Protection of Cftr knockout mice from acute lung infection by a helper-dependent adenoviral vector expressing Cftr in airway epithelia
David R. Koehler,Umadevi S. Sajjan,Yu Hua Chow,Bernard Martin,Geraldine Kent,A. Keith Tanswell,Colin McKerlie,Janet F. Forstner,Jim Hu +8 more
TL;DR: The development of a helper-dependent adenoviral vector for cystic fibrosis lung gene therapy and test of its therapeutic potential suggest that gene therapy could benefit patients by reducing susceptibility to opportunistic pathogens.
Journal ArticleDOI
Reduced inflammation and improved airway expression using helper-dependent adenoviral vectors with a K18 promoter.
TL;DR: Results suggest that delivery to the airway of helper-dependent adenoviral vectors utilizing a tissue-specific promoter could be a significant advance in the development of gene therapy for cystic fibrosis.